Advertisement

Topics

Tumour PD-L2 expression may predict patient response to anti-PD-1 immunotherapy

01:15 EDT 15 Jun 2017 | ecancermedicalscience

PD-L2 protein expression in human tumours was associated with clinical response to pembrolizumab (Keytruda), an anti-PD-1 immunotherapy, independent of PD-L1 expression, in patients with head and neck squamous cell carcinoma (HNSCC), according to research...

Original Article: Tumour PD-L2 expression may predict patient response to anti-PD-1 immunotherapy

NEXT ARTICLE

More From BioPortfolio on "Tumour PD-L2 expression may predict patient response to anti-PD-1 immunotherapy"

Quick Search
Advertisement
 

Relevant Topics

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...